Literature DB >> 24287730

Donor mesenchymal stromal cells (MSCs) undergo variable cardiac reprogramming in vivo and predominantly co-express cardiac and stromal determinants after experimental acute myocardial infarction.

Gustavo Yannarelli1, James N Tsoporis, Jean-Francois Desjardins, Xing Hua Wang, Ali Pourdjabbar, Sowmya Viswanathan, Thomas G Parker, Armand Keating.   

Abstract

We previously showed the emergence of predominantly non-fused murine cells co-expressing cardiac and stromal determinants in co-cultures of murine mesenchymal stromal cells (MSCs) and rat embryonic cardiomyocytes. To determine whether a similar phenotype is detectable in vivo in ischemic myocardium, we infused green fluorescence protein (GFP)-marked MSCs intravenously into wild-type mice in an acute myocardial infarction (AMI) model generated by ischemia/reperfusion (I/R) or fixed coronary artery ligation. We found that infused GFP+ cells were confined strictly to ischemic areas and represented approximately 10% of total cellularity. We showed that over 60% of the cells co-expressed collagen type IV and troponin T or myosin heavy chain, characteristic of MSCs and cardiomyocytes, respectively, and were CD45(-). Nonetheless, up to 25% of the GFP+ donor cells expressed one of two cardiomyocyte markers, either myosin heavy chain or troponin T, in the absence of MSC determinants. We also observed a marked reduction in OCT4 expression in MSCs pre-infusion compared with those lodged in the myocardium, suggesting reduced stem cell properties. Despite the low frequency of lodged donor MSCs, left-ventricular end-diastolic pressure was significantly better in experimental versus saline animals for both AMI (12.10 ± 1.81 vs. 20.50 ± 1.53 mmHg, p < 0.001) and I/R models (8.75 ± 2.95 vs. 17.53 ± 3.85 mmHg, p = 0.004) when measured 21 days after MSC infusion and is consistent with a paracrine effect. Our data indicate that donor MSCs undergo variable degrees of cardiomyocyte reprogramming with the majority co-expressing cardiomyocyte and stromal markers. Further studies are needed to elucidate the factors mediating the extent of cardiomyocyte reprogramming and importance of the cellular changes on tissue repair.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24287730     DOI: 10.1007/s12015-013-9483-y

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  43 in total

1.  Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction.

Authors:  Atta Behfar; Satsuki Yamada; Ruben Crespo-Diaz; Jonathan J Nesbitt; Lois A Rowe; Carmen Perez-Terzic; Vinciane Gaussin; Christian Homsy; Jozef Bartunek; Andre Terzic
Journal:  J Am Coll Cardiol       Date:  2010-08-24       Impact factor: 24.094

Review 2.  Bone marrow cells for cardiac repair.

Authors:  Armand Keating
Journal:  Biol Blood Marrow Transplant       Date:  2005-02       Impact factor: 5.742

3.  Enhanced recovery of mechanical function in the canine heart by seeding an extracellular matrix patch with mesenchymal stem cells committed to a cardiac lineage.

Authors:  Irina A Potapova; Sergey V Doronin; Damon J Kelly; Amy B Rosen; Adam J T Schuldt; Zhongju Lu; Paul V Kochupura; Richard B Robinson; Michael R Rosen; Peter R Brink; Glenn R Gaudette; Ira S Cohen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-03       Impact factor: 4.733

4.  Mesenchymal stem cells regulate angiogenesis according to their mechanical environment.

Authors:  Grit Kasper; Niels Dankert; Jens Tuischer; Moritz Hoeft; Timo Gaber; Juliane D Glaeser; Desiree Zander; Miriam Tschirschmann; Mark Thompson; Georg Matziolis; Georg N Duda
Journal:  Stem Cells       Date:  2007-01-11       Impact factor: 6.277

5.  Limited plasticity of mesenchymal stem cells cocultured with adult cardiomyocytes.

Authors:  Maria Pia Gallo; Roberta Ramella; Giuseppe Alloatti; Claudia Penna; Pasquale Pagliaro; Andrea Marcantoni; Francesca Bonafé; Gianni Losano; Renzo Levi
Journal:  J Cell Biochem       Date:  2007-01-01       Impact factor: 4.429

6.  Mobilized bone marrow cells repair the infarcted heart, improving function and survival.

Authors:  D Orlic; J Kajstura; S Chimenti; F Limana; I Jakoniuk; F Quaini; B Nadal-Ginard; D M Bodine; A Leri; P Anversa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

7.  Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction.

Authors:  Victor Dayan; Gustavo Yannarelli; Filio Billia; Paola Filomeno; Xing-Hua Wang; John E Davies; Armand Keating
Journal:  Basic Res Cardiol       Date:  2011-09-08       Impact factor: 17.165

Review 8.  Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review.

Authors:  Enca Martin-Rendon; Susan J Brunskill; Chris J Hyde; Simon J Stanworth; Anthony Mathur; Suzanne M Watt
Journal:  Eur Heart J       Date:  2008-06-03       Impact factor: 29.983

9.  Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: a quantitative assessment.

Authors:  Sharon L Hale; Wangde Dai; Joan S Dow; Robert A Kloner
Journal:  Life Sci       Date:  2008-08-09       Impact factor: 5.037

10.  Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts.

Authors:  Charles E Murry; Mark H Soonpaa; Hans Reinecke; Hidehiro Nakajima; Hisako O Nakajima; Michael Rubart; Kishore B S Pasumarthi; Jitka Ismail Virag; Stephen H Bartelmez; Veronica Poppa; Gillian Bradford; Joshua D Dowell; David A Williams; Loren J Field
Journal:  Nature       Date:  2004-03-21       Impact factor: 49.962

View more
  7 in total

Review 1.  Mesenchymal stromal cell therapy for the treatment of intestinal ischemia: Defining the optimal cell isolate for maximum therapeutic benefit.

Authors:  Dominique L Doster; Amanda R Jensen; Sina Khaneki; Troy A Markel
Journal:  Cytotherapy       Date:  2016-10-10       Impact factor: 5.414

2.  In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells.

Authors:  Peter Szaraz; Yarden S Gratch; Farwah Iqbal; Clifford L Librach
Journal:  J Vis Exp       Date:  2017-08-09       Impact factor: 1.355

3.  Comparison of human induced pluripotent stem-cell derived cardiomyocytes with human mesenchymal stem cells following acute myocardial infarction.

Authors:  Lucas Citro; Shan Naidu; Fatemat Hassan; M Lakshmi Kuppusamy; Periannan Kuppusamy; Mark G Angelos; Mahmood Khan
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

4.  Collagen scaffold enhances the regenerative properties of mesenchymal stromal cells.

Authors:  Iran Rashedi; Nilesh Talele; Xing-Hua Wang; Boris Hinz; Milica Radisic; Armand Keating
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

5.  Comparison of biological characteristics of mesenchymal stem cells derived from the human umbilical cord and decidua parietalis.

Authors:  Yu-Tao Guan; Yong Xie; Dong-Sheng Li; Yu-Yuan Zhu; Xiao-Lu Zhang; Ying-Lin Feng; Yang-Ping Chen; Li-Jiang Xu; Pin-Fu Liao; Gang Wang
Journal:  Mol Med Rep       Date:  2019-05-23       Impact factor: 2.952

6.  In Vitro Differentiation of First Trimester Human Umbilical Cord Perivascular Cells into Contracting Cardiomyocyte-Like Cells.

Authors:  Peter Szaraz; Matthew Librach; Leila Maghen; Farwah Iqbal; Tanya A Barretto; Shlomit Kenigsberg; Andrée Gauthier-Fisher; Clifford L Librach
Journal:  Stem Cells Int       Date:  2016-03-30       Impact factor: 5.443

7.  OCT4 expression mediates partial cardiomyocyte reprogramming of mesenchymal stromal cells.

Authors:  Gustavo Yannarelli; Natalia Pacienza; Sonia Montanari; Diego Santa-Cruz; Sowmya Viswanathan; Armand Keating
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.